Af­ter a rough year in the trench­es, Al­ny­lam CEO John Maraganore and his team take a big cut in com­pen­sa­tion

Al­ny­lam CEO John Maraganore had a tough year in 2016. In ear­ly Oc­to­ber the biotech’s stock plunged in the wake of his de­ci­sion to scrap a late-stage pro­gram. But since then the com­pa­ny $AL­NY has clawed back much of its lost mar­ket cap.

Now, to top it off, his com­pen­sa­tion has dropped pre­cip­i­tous­ly as the com­pa­ny looks to spread the wealth in new ways.

Ac­cord­ing to Al­ny­lam’s proxy state­ment, Maraganore’s to­tal com­pen­sa­tion for 2016 was $1,744,842 — far be­low the glo­ry days of 2015, when he scored to­tal com­pen­sa­tion of $8,261,158. Maraganore’s base pay edged up slight­ly to $731,600.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER